<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Autism</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Autism</journal-id>
<journal-title-group>
<journal-title>Molecular Autism</journal-title>
</journal-title-group>
<issn pub-type="epub">2040-2392</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26933487</article-id>
<article-id pub-id-type="pmc">4772588</article-id>
<article-id pub-id-type="publisher-id">80</article-id>
<article-id pub-id-type="doi">10.1186/s13229-016-0080-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Synaptic vesicle dynamic changes in a model of fragile X</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Broek</surname>
<given-names>Jantine A. C.</given-names>
</name>
<address>
<email>acb86@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Lin</surname>
<given-names>Zhanmin</given-names>
</name>
<address>
<email>z.lin@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>de Gruiter</surname>
<given-names>H. Martijn</given-names>
</name>
<address>
<email>h.degruiter@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van ‘t Spijker</surname>
<given-names>Heleen</given-names>
</name>
<address>
<email>hv248@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haasdijk</surname>
<given-names>Elize D.</given-names>
</name>
<address>
<email>e.haasdijk@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cox</surname>
<given-names>David</given-names>
</name>
<address>
<email>dac64@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ozcan</surname>
<given-names>Sureyya</given-names>
</name>
<address>
<email>so345@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Cappellen</surname>
<given-names>Gert W. A.</given-names>
</name>
<address>
<email>w.vancappellen@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Houtsmuller</surname>
<given-names>Adriaan B.</given-names>
</name>
<address>
<email>a.houtsmuller@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Willemsen</surname>
<given-names>Rob</given-names>
</name>
<address>
<email>r.willemsen@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff4"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Zeeuw</surname>
<given-names>Chris I.</given-names>
</name>
<address>
<email>c.dezeeuw@erasmusmc.nl</email>
</address>
<xref ref-type="aff" rid="Aff2"></xref>
<xref ref-type="aff" rid="Aff5"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Bahn</surname>
<given-names>Sabine</given-names>
</name>
<address>
<phone>44 (0) 1223 334 160</phone>
<email>sb209@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<aff id="Aff1"><label></label>Cambridge Centre for Neuropsychiatric Research, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK </aff>
<aff id="Aff2"><label></label>Department of Neurosciences, Erasmus MC, Rotterdam, The Netherlands </aff>
<aff id="Aff3"><label></label>Erasmus Optical Imaging Center, Erasmus MC, Rotterdam, The Netherlands </aff>
<aff id="Aff4"><label></label>Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands </aff>
<aff id="Aff5"><label></label>Netherlands Institute for Neurosciences, Royal Academy for Arts and Sciences, Amsterdam, The Netherlands </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>1</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>7</volume>
<elocation-id>17</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© Broek et al. 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p>Fragile X syndrome (FXS) is a single-gene disorder that is the most common heritable cause of intellectual disability and the most frequent monogenic cause of autism spectrum disorders (ASD). FXS is caused by an expansion of trinucleotide repeats in the promoter region of the fragile X mental retardation gene (<italic>Fmr1</italic>). This leads to a lack of fragile X mental retardation protein (FMRP), which regulates translation of a wide range of messenger RNAs (mRNAs). The extent of expression level alterations of synaptic proteins affected by FMRP loss and their consequences on synaptic dynamics in FXS has not been fully investigated.</p>
</sec>
<sec>
<title>Methods</title>
<p>Here, we used an <italic>Fmr1</italic> knockout (KO) mouse model to investigate the molecular mechanisms underlying FXS by monitoring protein expression changes using shotgun label-free liquid-chromatography mass spectrometry (LC-MS<sup>E</sup>) in brain tissue and synaptosome fractions. FXS-associated candidate proteins were validated using selected reaction monitoring (SRM) in synaptosome fractions for targeted protein quantification. Furthermore, functional alterations in synaptic release and dynamics were evaluated using live-cell imaging, and interpretation of synaptic dynamics differences was investigated using electron microscopy.</p>
</sec>
<sec>
<title>Results</title>
<p>Key findings relate to altered levels of proteins involved in GABA-signalling, especially in the cerebellum. Further exploration using microscopy studies found reduced synaptic vesicle unloading of hippocampal neurons and increased vesicle unloading in cerebellar neurons, which suggests a general decrease of synaptic transmission.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Our findings suggest that FMRP is a regulator of synaptic vesicle dynamics, which supports the role of FMRP in presynaptic functions. Taken together, these studies provide novel insights into the molecular changes associated with FXS.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1186/s13229-016-0080-1) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Fragile X syndrome (FXS)</kwd>
<kwd>Synaptic transmission</kwd>
<kwd>Mass spectrometry (MS)</kwd>
<kwd>Quantitative live-cell imaging</kwd>
<kwd>Electron microscopy</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p>Fragile X syndrome (FXS, OMIM: #300624) is a single-gene disorder causing a heritable form of mental impairment (WHO, 1996), with a prevalence in males ranging from 1/4000 to 1/5161 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Core cognitive deficits found in FXS-patients include problems with short-term and working memory, executive function deficits and mathematical and visuospatial difficulties [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, 60–74 % of male FXS patients meet the criteria for autism spectrum disorder (ASD), and 2–6 % of ASD patients are identified to suffer from FXS [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In spite of the clear monogenetic cause of FXS, the cellular consequences of fragile X mental retardation protein (FMRP) depletion are widespread and remain poorly understood. FMRP is known for its role in messenger RNA (mRNA) binding, transport activity and subsequent translation regulation upon metabotropic glutamate receptor 5 (mGluR5) stimulation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Synaptic dysfunction would be expected both in the pre- and postsynaptic regions. The systems found to be affected at the presynapse include synaptic vesicles [<xref ref-type="bibr" rid="CR8">8</xref>] and plasticity via short-term depression [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Despite the indication of synaptic differences in the pathogenesis of FXS, the underlying mechanisms of synaptic dysfunction in FXS remain to be investigated.</p>
<p>In this study, a fragile X mental retardation 1 gene (<italic>Fmr1</italic>) KO mouse model was used to study synaptic changes in the hippocampus and cerebellum. In the first part, both brain tissue and synaptosomes were subjected to molecular profiling analyses using a combination of liquid-chromatography mass spectrometry (LC-MS<sup>E</sup>) and selected reaction monitoring mass spectrometry (SRM-MS) to detect and validate protein changes (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). We found that in the absence of FMRP, most of the protein changes occurred at the synapse, which is in line with previous studies indicating differences in signal transduction, neuronal development and GABA/glutamate neurotransmission. Therefore, the second part of this study was focused on quantitative live-cell imaging investigating synaptic vesicle recycling in primary hippocampal and cerebellar neurons and electron microscopy to investigate potential presynaptic structure differences in the cerebellum. These studies indicated differences in the dynamics of synaptic vesicle turn-over, and together with the identified protein changes, we hypothesise that disturbances of synaptic dynamics are linked to fragile X syndrome.<fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of experimental design. In the mass spectrometry studies, the Fmr1 KO mouse model was compared with WT mice. Frontal cortex, hippocampal and cerebellar brain tissues were used for protein profiling using LC-MS<sup>E</sup>. For synaptosomes, both hippocampal and cerebellar tissues were used for LC-MS<sup>E</sup> and SRM-MS studies. Data analysis resulted in the identification of significant protein changes. For live-cell imaging, neurons of the Fmr1 KO mouse model were cultured and compared with WT mice for both hippocampus and cerebellum. These neurons were stained with FM1-43 dye that specifically stains synaptic vesicles. For electron microscopy, Fmr1 was specifically knocked down in Purkinje cells and these cells were used for ultrastructural analysis. Data analysis was performed in instrument specific programmes, and statistical analysis was performed using R statistical programming language</p></caption><graphic id="MO1" xlink:href="13229_2016_80_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Animal model</title>
<p><italic>Fmr1</italic> knockout (KO) mice and wild type (WT) littermates on a congenic C57BL/6 background were provided by the Clinical Genetics group at Erasmus MC, The Netherlands. The mouse experiments were approved in advance by the Institutional Animal Welfare Committee (Erasmus MC, Rotterdam, The Netherlands). Mouse brain tissue samples used for LC-MS<sup>E</sup> experiments were obtained by crossing FVB/Ant x heterozygous <italic>Fmr1</italic> KO(2) to test hybrid mice with 50 % FVB/Ant and 50 % C57BL/6 contributions [<xref ref-type="bibr" rid="CR11">11</xref>]. Both lines were inbred (&gt;10 times backcrossed). All mice were male, aged 14 weeks old, with an average weight of 30.2 +/− 2.0 g for <italic>Fmr1</italic> KO and 29.2 +/− 2.5 g for wild type (WT) mice and were tested on the ErasmusLadder (for data obtained with the ErasmusLadder see [<xref ref-type="bibr" rid="CR12">12</xref>]). After the training period, 11 <italic>Fmr1</italic> KO and 12 WT male mice were killed and the bilateral hippocampi, frontal cortices and cerebella were dissected. All mice were sacrificed by cervical dislocation, and brains were dissected immediately.</p>
<p><italic>Fmr1</italic> KO(2) mice and WT littermates [<xref ref-type="bibr" rid="CR11">11</xref>] were used to obtain synaptosomal fractions as described by Schrimpf and colleagues [<xref ref-type="bibr" rid="CR13">13</xref>]. Compared to the brain tissue samples, the background of these mice was C57BL/6 and backcrossing occurred for more than 10 generations. Synaptosomal fractions were obtained from the hippocampi (<italic>n</italic> = 10/group) and cerebella (<italic>n</italic> = 10/group), and these samples were used for homogenization and stepwise centrifugation to remove cell debris and to extract the synaptosomes [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p>For neuronal cultures, E18 <italic>Fmr1</italic> KO(2) and WT mouse embryos with a C57BL/6 background [<xref ref-type="bibr" rid="CR11">11</xref>] were decapitated and both the hippocampi and the cerebella were dissected and used for neuronal cell culture (see Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 22). For electron microscopy, Purkinje cell-specific <italic>Fmr1</italic> KO mice with a C57BL/6 background were generated via deletion of the first coding exon of <italic>Fmr1</italic> through Cre-mediated recombination, as described by Koekkoek and colleagues [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
</sec>
<sec id="Sec4">
<title>Protein digestion</title>
<p>Sample preparation was performed as previously described for both non-targeted and targeted studies (see Additional file <xref ref-type="media" rid="MOESM1">1</xref>, pages 1–4) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In short, samples were reduced and alkylated prior to tryptic digestion. Quality control (QC) samples were created by pooling all samples after alkylation.</p>
</sec>
<sec id="Sec5">
<title>Label-free LC-MS<sup>E</sup> protein profiling</title>
<p>Reverse-phase ultra performance-liquid chromatography (UPLC), using C-18 columns, was coupled to a Q-TOF Premier™ MS (Waters) system through a nano-electron spray ionization (ESI) online emitter (see Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 2). LC-MS<sup>E</sup> data was processed using ProteinLynx Global Server v.2.5 (Waters Corporation) and Rosetta Elucidator v.3.3 (Rosetta Biosoftware, Seattle, WA). Criteria for protein identification were ≥3 fragment ions per peptide, ≥7 fragment ions per protein and ≥2 peptides per protein.</p>
</sec>
<sec id="Sec6">
<title>Targeted protein quantification</title>
<p>Candidate proteins, chosen based on in silico pathway analyses of the LC-MS<sup>E</sup> results, as described in Additional file <xref ref-type="media" rid="MOESM1">1</xref>, pages 1–15, as well as proteins associated with FMRP in the literature, were further validated and quantified using targeted selected reaction monitoring mass spectrometry (SRM-MS) on a Xevo TQ-S mass spectrometer coupled to a nanoAcquity UPLC system (Waters Corporation). Criteria for selecting tryptic peptides were based on peptide count, uniqueness and quality of transitions. Two peptides were selected for each target protein and isotopically labelled peptides were synthesised at JPT Peptide Technologies GmbH (Berlin, Germany). At least three transitions were measured for each peptide, and each sample was analysed in triplicate. Isotopically labelled synthetic peptides were spiked into the samples as an internal standard prior to MS analysis. The candidate proteins were validated and quantified with SRM mass spectrometry as described previously [<xref ref-type="bibr" rid="CR15">15</xref>]. Due to the observation that most of the proteins identified in the initial LC-MS<sup>E</sup> discovery study were located at the synapse, the proteomic profiles of synaptosome fraction were investigated using LC-MS<sup>E</sup> as well as SRM for validation purposes.</p>
</sec>
<sec id="Sec7">
<title>Statistical analysis of mass spectrometry data</title>
<p>Both LC-MS<sup>E</sup> and SRM data were analysed in the R statistical programming language (version 3.1.1 [<xref ref-type="bibr" rid="CR17">17</xref>]) using the MSstats package (Purdue University; West Lafayette, IN, USA), which provides wrapper functions to simplify the fitting of linear mixed effects models. The data of the identified proteins were log<sub>2</sub> transformed and normalised for the intensities of the peaks. For the label-free LC-MS<sup>E</sup> experiment, constant normalization was performed based on endogenous signals across runs among all proteins. Peptide transitions were excluded based upon a between-run-interference score &lt;0.8, where the score was based on the correlation between mean of peptide by run and peptide transition intensity. Analysis was performed using linear mixed models to detect differentially expressed proteins between groups, as this approach can handle the hierarchical structure of the data. The interference for biological replicates and technical replicates was used in expanded scope, which expands the conclusion from the model to the population of biological units [<xref ref-type="bibr" rid="CR18">18</xref>]. We considered results significant when proteins were found to be changed by more than 10 % and with a <italic>p</italic> value &lt;0.05. These analyses resulted in <italic>p</italic> values, <italic>q</italic> values (Benjamini&amp;Hochberg method) and ratio changes (<italic>Fmr1</italic>/WT).</p>
<p>For SRM-MS analysis, proteins with a peptide count (PC) &gt;2, <italic>p</italic> value &lt;0.05 and a ratio &gt;10 % were included. Difference from the LC-MS<sup>E</sup> analysis was that constant normalization was performed based on reference signals across runs among all proteins, and quantification was based on the ratio between endogenous and reference intensity. Data was analysed using a linear mixed model in restricted scope, which limits the conclusion from the model to observed biological units [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
<p>Furthermore, protein-protein interaction networks were constructed from the significantly changed proteins by finding first-degree interacting neighbours as described in the Additional file <xref ref-type="media" rid="MOESM1">1</xref>, pages 16–21.</p>
</sec>
<sec id="Sec8">
<title>Analysis of live-cell imaging and electron microscopy</title>
<p>The synaptic boutons, visualized in primary neurons as described in the Additional file <xref ref-type="media" rid="MOESM1">1</xref>, pages 22–25, were analysed by identifying regions of interest (ROIs) using Fiji [<xref ref-type="bibr" rid="CR19">19</xref>]. Sample movement was corrected using StackReg [<xref ref-type="bibr" rid="CR20">20</xref>], and synaptic boutons were detected and tracked using a semi-automated procedure implemented in Fiji plug-in (available from <ext-link ext-link-type="uri" xlink:href="http://smal.ws/wp/software/sosplugin/">http://smal.ws/wp/software/sosplugin/</ext-link>[<xref ref-type="bibr" rid="CR21">21</xref>]). Briefly, synaptic boutons were detected by fitting Gaussian distributions with sigma corresponding to bouton sizes ranging from 300–800 nm. To differentiate between synaptic boutons and trafficking synaptic vesicles, tracks were created using a nearest-neighbour linking approach for objects moving less than 500 nm within three frames. Tracks were visualized and quantified with the MTrackJ plug-in of Fiji [<xref ref-type="bibr" rid="CR22">22</xref>]. The identification of different unloading profiles, the weak and strong unloading synaptic boutons, was performed as described before [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
<p>In R statistical programming language (version 3.1.1 [<xref ref-type="bibr" rid="CR17">17</xref>]), the MTrackJ results and background values were imported and relevant tracks were selected based on starting time point and minimum time point length. Baseline correction was performed by normalizing the tracks for baseline intensity. To identify the two different unloading profiles, tracks were hierarchically clustered in sub-populations based on the decrease of signal immediately after stimulation. The threshold criteria for clustering were (1) a decrease of the slope after stimulation of 25 %, (2) a relative amount of variation based on a ratio stdev/mean intensity lower than 0.5 and (3) stability of the baseline slope. Statistical analysis was performed using a <italic>t</italic> test with permutations to look for differences in the amount of synaptic boutons and analysis of variance (ANOVA) to compare the regression lines of the synaptic bouton dye release.</p>
<p>Furthermore, the ultrastructural data obtained by electron microscopy (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 26) were statistical analysed in R using a <italic>t</italic> test with permutations (AZ length, presynaptic area and vesicle density) and correlation (density with AZ length).</p>
</sec>
</sec>
<sec id="Sec9">
<title>Results</title>
<sec id="Sec10">
<title>Quantitative LC-MS<sup>E</sup> proteomic profiling of mouse frontal cortex, hippocampus and cerebellum</title>
<p>LC-MS<sup>E</sup> profiling was carried out to determine the effects of the absence of the FMRP protein in mouse brain. Previous studies have indicated that the cerebellum [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] and hippocampus [<xref ref-type="bibr" rid="CR7">7</xref>] are prominently affected in FXS. Moreover, since frontal cortex dysfunction is known to play a key part in autism [<xref ref-type="bibr" rid="CR25">25</xref>], we investigated the frontal cortex additionally. After data filtering, the analysis resulted in the identification of 553 (frontal cortex), 705 (hippocampus) and 536 (cerebellum) proteins, respectively. Following data quality assessment, 24 proteins were significantly different in the frontal cortex, 14 in the hippocampus and 11 in the cerebellum (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 6). GO-enrichment analysis was performed to detect first-degree neighbour proteins using all significantly changed proteins with a ratio <italic>Fmr1</italic> KO/WT of &gt;10 % (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 16). The significant findings of the profiling study were predominantly proteins located at the synapse, such as ATPases and proteins important for neurotransmitter signalling (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 9).</p>
</sec>
<sec id="Sec11">
<title>Quantitative LC-MS<sup>E</sup> proteomic profiling of synaptosome fractions isolated from the hippocampus and cerebellum</title>
<p>In the synaptosome fraction study, the hippocampus and cerebellum were prioritised as these are predominantly affected in FXS. LC-MS<sup>E</sup> analysis of mouse synaptosomes resulted in the identification of 1114 (hippocampus) and 1040 (cerebellum) proteins, respectively. After data filtering, the number of significant proteins were 23 (hippocampus) and 13 (cerebellum) (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 11). In GO enrichment, fewer networks are indicated for the synaptosome fractions compared to brain tissue, as fewer significant proteins were indicated (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 20). The main protein changes are involved in synaptic signalling, neurotransmission, synaptic vesicles and neuron development (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 14). Overlap of significantly altered networks between brain tissue and synaptosome fractions indicated protein dephosphorylation and synaptic signalling, such as glutamate pathways and dendrite morphogenesis, as changed in common (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 21). Therefore, proteins involved in synaptic signalling as found in the protein profiling study of the synaptosome fractions and in brain tissue (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 9, 14) were taken forward for targeted SRM analysis.</p>
</sec>
<sec id="Sec12">
<title>Targeted SRM-MS validation of hippocampal and cerebellar synaptosome fractions</title>
<p>An SRM-MS assay panel was developed to validate changes related to signal transduction, neuronal development and neurotransmission, including isoforms of the theme proteins and proteins known to relate to FXS from the literature. The results show that most of the significantly changed proteins in the hippocampus were decreased in abundance, while proteins significantly changed in the cerebellum were increased (Table <xref ref-type="table" rid="Tab1">1</xref>). In the hippocampus, a significant decrease was found for proteins associated with neuronal development and GABA/glutamate neurotransmission, as well as significantly different levels of two ATPases. Most significant protein changes were observed in the cerebellum, with a general increase of abundance in ATPases and GABA/glutamate-related proteins. Furthermore, several neuronal development proteins were significantly different. FMRP-related protein CYFP1 was found to be significantly changed in abundance in both the hippocampus and cerebellum, while CYFP2 and FXR2 were only changed in the cerebellum (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Protein changes validated using SRM-MS in the mouse brain synaptosome fractions</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="3">HC</th><th colspan="3">CB</th></tr><tr><th>Protein name</th><th>Ratio Fmr1 KO/WT</th><th>
<italic>p</italic> value</th><th>
<italic>q</italic> value</th><th>Ratio Fmr1 KO/WT</th><th>
<italic>p</italic> value</th><th>
<italic>q</italic> value</th></tr></thead><tbody><tr><td>Signal transduction</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Plasma membrane calcium-transporting ATPase 2 (AT2B2)<sup>a, b, e</sup>
</td><td>1.11</td><td>0.6403</td><td>0.8270</td><td>1.16</td><td>0.2314</td><td>0.2953</td></tr><tr><td> Sodium potassium transporting ATPase alpha 1 (AT1A1)<sup>a</sup>
</td><td>0.99</td><td>0.8710</td><td>0.9194</td><td>1.32</td><td>
<italic>2.60*10</italic>
<sup><italic>−11</italic></sup>
</td><td>
<italic>3.20*10</italic>
<sup><italic>−10</italic></sup>
</td></tr><tr><td> Sodium potassium transporting ATPase alpha 3 (AT1A3)<sup>a</sup>
</td><td>0.74</td><td>
<italic>0.0076</italic>
</td><td>
<italic>0.0480</italic>
</td><td>1.66</td><td>
<italic>2.50*10</italic>
<sup><italic>−07</italic></sup>
</td><td>
<italic>1.03*10</italic>
<sup><italic>−06</italic></sup>
</td></tr><tr><td> Sodium potassium transporting ATPase beta 1 (AT1B1)<sup>a</sup>
</td><td>1.01</td><td>0.9524</td><td>0.9524</td><td>1.27</td><td>
<italic>2.63*10</italic>
<sup><italic>−10</italic></sup>
</td><td>
<italic>2.43*10</italic>
<sup><italic>−09</italic></sup>
</td></tr><tr><td> Sodium potassium transporting ATPase beta 2 (AT1B2)<sup>a</sup>
</td><td>1.21</td><td>
<italic>0.0509</italic>
</td><td>0.1874</td><td>1.19</td><td>
<italic>0.0122</italic>
</td><td>
<italic>0.0215</italic>
</td></tr><tr><td> Synaptic vesicle glycoprotein 2A (SV2A)<sup>b, d</sup>
</td><td>1.02</td><td>0.6529</td><td>0.8270</td><td>1.20</td><td>
<italic>0.0002</italic>
</td><td>
<italic>0.0005</italic>
</td></tr><tr><td> Synaptic vesicle glycoprotein 2B (SV2B)<sup>b</sup>
</td><td>0.86</td><td>0.1754</td><td>0.3715</td><td>0.92</td><td>0.5270</td><td>0.5909</td></tr><tr><td>Neuronal development</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Brain acid soluble protein 1 (BASP1)<sup>c</sup>
</td><td>0.77</td><td>
<italic>&lt;2.60*10</italic>
<sup><italic>−11</italic></sup>
</td><td>
<italic>&lt;2.60*10</italic>
<sup><italic>−11</italic></sup>
</td><td>1.75</td><td>
<italic>8.15*10</italic>
<sup><italic>−07</italic></sup>
</td><td>
<italic>3.02*10</italic>
<sup><italic>−06</italic></sup>
</td></tr><tr><td> Neuromodulin (NEUM)<sup>a</sup>
</td><td>0.88</td><td>
<italic>0.0751</italic>
</td><td>0.1874</td><td>0.77</td><td>
<italic>0.0071</italic>
</td><td>
<italic>0.0146</italic>
</td></tr><tr><td>Neurotransmission: GABA/glutamate-related proteins</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> BTB POZ domain containing protein KCTD12 (KCD12)<sup>a</sup>
</td><td>0.73</td><td>
<italic>0.38*10</italic>
<sup><italic>−05</italic></sup>
</td><td>0.0004</td><td>1.17</td><td>
<italic>0.0098</italic>
</td><td>
<italic>0.0192</italic>
</td></tr><tr><td> Glutamate receptor 1 (GRIA1)<sup>b, d</sup>
</td><td>0.83</td><td>
<italic>0.0789</italic>
</td><td>0.1874</td><td>1.77</td><td>
<italic>1.35*10</italic>
<sup><italic>−07</italic></sup>
</td><td>
<italic>6.24*10</italic>
<sup><italic>−07</italic></sup>
</td></tr><tr><td> Glutamate receptor 3 (GRIA3)<sup>b, d</sup>
</td><td>0.87</td><td>0.1760</td><td>0.3715</td><td>1.34</td><td>
<italic>0.0160</italic>
</td><td>
<italic>0.0269</italic>
</td></tr><tr><td> Succinate semialdehyde dehydrogenase (SSDH)<sup>a</sup>
</td><td>1.06</td><td>0.3880</td><td>0.5897</td><td>0.93</td><td>0.3833</td><td>0.4432</td></tr><tr><td> Vesicular glutamate transporter 1 (VGLU1)<sup>a</sup>
</td><td>1.02</td><td>0.8017</td><td>0.8934</td><td>1.23</td><td>
<italic>0.0222</italic>
</td><td>
<italic>0.0342</italic>
</td></tr><tr><td> Excitatory amino acid transporter 1 (EAA1)<sup>a</sup>
</td><td>1.14</td><td>0.3178</td><td>0.5251</td><td>1.13</td><td>0.3431</td><td>0.4095</td></tr><tr><td> Glutamate decarboxylase 1 (DCE1)<sup>b</sup>
</td><td>0.94</td><td>0.6107</td><td>0.8270</td><td>0.95</td><td>0.7279</td><td>0.7782</td></tr><tr><td> Glutamate decarboxylase 2 (DCE2)<sup>b, d</sup>
</td><td>0.81</td><td>0.3422</td><td>0.5419</td><td>1.27</td><td>0.2416</td><td>0.2979</td></tr><tr><td>FMRP-related proteins</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Cytoplasmic FMR1-interacting protein 1 (CYFP1)<sup>b, d</sup>
</td><td>0.65</td><td>
<italic>0.0205</italic>
</td><td>0.0973</td><td>1.45</td><td>
<italic>0.0437</italic>
</td><td>
<italic>0.0621</italic>
</td></tr><tr><td> Cytoplasmic FMR1-interacting protein 2 (CYFP2)<sup>b</sup>
</td><td>1.04</td><td>0.7761</td><td>0.8934</td><td>1.41</td><td>
<italic>0.0217</italic>
</td><td>
<italic>0.0342</italic>
</td></tr><tr><td> Fragile X mental retardation syndrome-related 2 (FXR2)<sup>c</sup>
</td><td>1.04</td><td>0.7108</td><td>0.8713</td><td>1.26</td><td>
<italic>0.0070</italic>
</td><td>
<italic>0.0146</italic>
</td></tr></tbody></table><table-wrap-foot><p>* this is the multiply sign</p><p>The table includes Uniprot ID, ratios (calculated based on average), <italic>P</italic> values and adjusted <italic>P</italic> values (Q). Significant proteins are indicated in italics</p><p>
<sup>a</sup>Proteins indicated in LC-MS<sup>E</sup> brain study</p><p>
<sup>b</sup>Proteins indicated in LC-MS<sup>E</sup> synaptosome study</p><p>
<sup>c</sup>Proteins associated with FMRP in literature</p><p>
<sup>d</sup>Isoforms of indicated proteins in B or S</p><p>
<sup>e</sup>Family member of proteins indicated in B or S</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec13">
<title>Identification of synaptic boutons using live-cell imaging</title>
<p>We could distinguish different unloading frequencies of the synaptic boutons, which resulted in strong (35 % intensity decrease after stimulation compared to baseline) and weak (18 % intensity decrease) FM1-43 unloading profiles as described in Bartolome-Martin [<xref ref-type="bibr" rid="CR23">23</xref>] (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, pages 22–24). After identification of the different unloading profiles, the number of synaptic boutons was counted, which showed no differences in the number of synaptic bouton unloading profiles in either the hippocampus or the cerebellum (Additional file <xref ref-type="media" rid="MOESM1">1</xref>, page 25). This result suggests that the number of synaptic boutons in cultured neurons are comparable between the <italic>Fmr1</italic> KO and WT mice, and as dye loading and unloading involve the same stimulation protocol (50 mM K<sup>+</sup>, 5 min), any differences in unloading kinetics are likely to reflect an alteration in synaptic vesicle dynamics.</p>
</sec>
<sec id="Sec14">
<title>Synaptic bouton dynamics in live-cell imaging</title>
<p>In live-cell imaging, the weak unloading boutons had an intercept of 0.91 relative intensity (RI) (<italic>Fmr1</italic> KO) and 0.79 RI (WT) in the hippocampus and 0.81 RI (<italic>Fmr1</italic> KO) and 0.88 RI (WT) in the cerebellum. The intercepts of the strong unloading boutons were 0.64 RI (<italic>Fmr1</italic> KO) and 0.61 RI (WT) for hippocampal neurons and 0.41 RI (<italic>Fmr1</italic> KO) and 0.59 RI (WT) for cerebellar neurons. Determining the difference in rate of dye release showed a significant decrease of both unloading profiles in <italic>Fmr1</italic> KO compared to WT mice in the hippocampus (weak unloading boutons: <italic>p</italic> value = 0.004; strong unloading boutons: <italic>p</italic> value = 0.008; Fig. <xref ref-type="fig" rid="Fig2">2</xref>). The synaptic vesicle dynamics in the cerebellum showed a significant increase of unloading activity in <italic>Fmr1</italic> KO mice compared to WT (weak unloading boutons: <italic>p</italic> value = 2.17 × 10<sup>−9</sup>; strong unloading boutons: <italic>p</italic> value = 2 × 10<sup>−16</sup>; Fig. <xref ref-type="fig" rid="Fig2">2</xref>). This implies that <italic>Fmr1</italic> KO cerebellar neurons have a higher turn-over rate of synaptic vesicle recycling.<fig id="Fig2"><label>Fig. 2</label><caption><p>Differences in synaptic bouton unloading of FM1-43 dye in hippocampal (HC) and cerebellar (CB) neurons. (<italic>top left</italic>) Weak unloading boutons are less synaptically active, which translates into the release of fewer synaptic vesicles and neurotransmitters. Strong unloading boutons have a greater number of synaptic vesicle exocytosis and are therefore expected to release neurotransmitters more actively. Kinetics of FM1-43 unloading of weak unloading boutons in the hippocampus showed a significant difference with a <italic>p</italic> value of 0.004 during stimulation with 50 mM KCl and (<italic>top right</italic>) a significant difference with a <italic>p</italic> value of 0.008 for strong unloading boutons in the hippocampus. In the cerebellum, the weak unloading boutons showed a highly significant change with a <italic>p</italic> value of 2.17 × 10<sup>−9</sup> (<italic>below left</italic>), as well as a highly significant change with a <italic>p</italic> value of 2 × 10<sup>−16</sup> for strong unloading of FM1-43 dye from synaptic boutons (<italic>below right</italic>). The <italic>p</italic> values were obtained by regression analysis with ANOVA comparing Fmr1 KO with WT mouse primary neurons</p></caption><graphic id="MO2" xlink:href="13229_2016_80_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec15">
<title>Ultrastructural analysis of cerebellar Purkinje cells</title>
<p>Statistical <italic>t</italic> test with permutation of the labelled Purkinje cell terminals (Fig. <xref ref-type="fig" rid="Fig3">3</xref>) was performed and showed no significant difference for active zone (AZ) length (<italic>p</italic> value = 0.583), presynaptic area (<italic>p</italic> value = 0.357) and synaptic vesicle density (<italic>p</italic> value = 0.543). When synaptic vesicle density was correlated with the AZ length, we found a negative correlation of <italic>r</italic> = −0.36 (<italic>p</italic> value = 0.206) for the <italic>Fmr1</italic> KO and a correlation of <italic>r</italic> = 0.059 (<italic>p</italic> value = 0.7364) for WT mice. These results imply that the unloading activity at the synapse as observed in live-cell imaging is caused by a higher turn-over rate of synaptic vesicle recycling and not by an increased number of synaptic vesicles.<fig id="Fig3"><label>Fig. 3</label><caption><p>Ultrastructural analysis of Purkinje cell synapses. Fmr1 KO (<bold>a</bold>) as compared to WT (<bold>b</bold>) Purkinje cell synapses revealed a negative correlation of density vs. active zone (AZ) length in Fmr1 KO (<bold>c</bold>), while this was positive for WT (<bold>d</bold>). <bold>e</bold>–<bold>g</bold> No significant differences were observed for AZ length, presynaptic area and vesicle density. In <bold>a</bold> and <bold>b</bold>: <italic>white rectangle</italic>= AZ; <italic>white circle</italic>= synaptic vesicles; and <italic>dark stained area</italic>= presynaptic area</p></caption><graphic id="MO3" xlink:href="13229_2016_80_Fig3_HTML"></graphic></fig></p>
</sec>
</sec>
<sec id="Sec16">
<title>Discussion</title>
<p>Here, we present a comprehensive study combining proteomic and microscopic investigations in an <italic>Fmr1</italic> KO mouse model. We employed orthogonal quantitative and qualitative proteomic approaches, live-cell visualization of synaptic vesicle dynamics and ultrastructural analyses of synapses to investigate protein alterations and their functional effects at the synapse in the context of FMRP deletion. Our findings provide evidence that molecular processes in synaptic transmission are affected in the hippocampus and cerebellum of the <italic>Fmr1</italic> KO mouse model. Surprisingly, most of the significantly affected proteins were identified in the cerebellum, which comprises changes in proteins associated with signal transduction, neuronal development and GABA/glutamate neurotransmission. The finding that the cerebellum is a prominently affected brain region is in line with behavioural findings using the ErasmusLadder, demonstrating major deficits in associative motor learning in <italic>Fmr1</italic> KO mice [<xref ref-type="bibr" rid="CR12">12</xref>]. In the microscopy studies, we found that a lack of FMRP leads to changes in synaptic vesicle unloading dynamics, with a strong increase of synaptic vesicle turn-over in cerebellar neurons and a decrease in hippocampal neurons. Therefore, alterations in synaptic vesicle dynamics due to loss of FMRP likely contribute to aberrant synaptic transmission in FXS patients. Recently, Myrick and colleagues found protein synthesis-independent presynaptic function for FMRP, using <italic>Drosophila melanogaster</italic> models with a missense mutation of a patient with a partial FXS phenotype [<xref ref-type="bibr" rid="CR26">26</xref>]. Our results together with previous studies suggest that FMRP regulates translation of proteins important for synaptic plasticity, indicating that FMRP has specific pre-and postsynaptic functions that contribute to different components of the FXS pathophysiology [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
<p>The proteomic study showed that FMRP loss resulted in changes in protein levels at the synapse, specifically in proteins involved in signal transduction, neuronal development and neurotransmission. The SRM-MS study of the synaptosome fractions indicated that proteins associated with signal transduction mainly relate to ATPases, which are proteins that contribute to creating an ion gradient across the synaptic membrane and therefore are important for synaptic transmission [<xref ref-type="bibr" rid="CR28">28</xref>]. A functional link between glutamate action and ATPase activity can be inferred from the observation that glutamate, through metabotropic receptors, is able to increase ATPase activity in Purkinje neurons [<xref ref-type="bibr" rid="CR29">29</xref>]. In the cerebellum, both the glutamate and GABA receptors were increased in expression, whereas they were decreased in the hippocampus, which might implicate that the excitability of neurons is changed. Changes in glutamate and GABA have been observed before in fragile X animal investigations, resulting in the mGluR theory and hypo-inhibition of GABA [<xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, VGLU1, a protein that mediates the uptake of glutamate into synaptic vesicles, and SV2A, important for fusion of synaptic vesicles to the membrane, were significantly increased in the cerebellum. A previous proteomic study using primary <italic>Fmr1</italic> KO hippocampal mouse neurons also identified changes in the SV2A protein [<xref ref-type="bibr" rid="CR30">30</xref>]. Other synaptic vesicle changes in the hippocampus indicate smaller active zones and pools of clustered vesicles [<xref ref-type="bibr" rid="CR31">31</xref>], a decrease of vesicle recruitment [<xref ref-type="bibr" rid="CR8">8</xref>] and abnormal short-term plasticity [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition, synaptic plasticity regulators BASP1 and NEUM, which are important for synaptic vesicle recycling, were found to be significantly changed in both the hippocampus and cerebellum, of which BASP1 is a consistent finding observed in previous studies in the hippocampus [<xref ref-type="bibr" rid="CR31">31</xref>]. Overall, this proteomic investigation provides evidence that loss of FMRP in the mouse brain alters synaptic signalling due to changes the in regulation of membrane potential and neurotransmitter release, which is in line with previous findings [<xref ref-type="bibr" rid="CR26">26</xref>]. Using SRM-MS, we also found a significant change in the expression of FMRP-associated protein CYFP1 [<xref ref-type="bibr" rid="CR32">32</xref>], both in hippocampal and cerebellar synaptosome fractions. Changes in FXR2 [<xref ref-type="bibr" rid="CR33">33</xref>] correlated with changes in CYFP2 [<xref ref-type="bibr" rid="CR32">32</xref>], which could be due to their interaction [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
<p>Investigating synaptic transmission using microscopy showed an increase of synaptic vesicle recycling in cerebellar neurons, which is held true for both boutons with weak and strong unloading. The majority of cerebellar neurons consist of Purkinje cells, which represent the main GABAergic inhibitory neuronal output from the cerebellum. An increase of synaptic vesicle recycling in cerebellar neurons might represent an increase of inhibitory output from the cerebellum. Since the amount of synaptic vesicles, active zone length and presynaptic area were not changed in the Purkinje cell axon terminals, the changes in synaptic vesicle recycling is mainly dynamic. These findings raise the question to what extent the enhanced LTD observed in <italic>Fmr1</italic> KO Purkinje cells [<xref ref-type="bibr" rid="CR14">14</xref>] reflects a compensatory process rather than a primary defect. Indeed, it is possible that homeostatic mechanisms through the olivocerebellar loop regulate the level of synaptic plasticity in Purkinje cells so as to stabilise the output of the cerebellar nuclei [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
<p>Decreased synaptic transmission in mouse amygdalae, neocortex and rat dorsal root ganglia have been observed before [<xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR38">38</xref>]. These studies together with the increase in long-term depression (LTD), as stated by the mGluR theory [<xref ref-type="bibr" rid="CR7">7</xref>], imply a decrease of synaptic transmission in the FXS hippocampus. Interestingly, the study of Deng (2011) suggested increased synaptic transmission in the hippocampus, due to increased short-term plasticity (STP) [<xref ref-type="bibr" rid="CR10">10</xref>]. However, Klemmer (2011) found reduced synaptic transduction resulting from a decreased number of synaptic vesicles, a shorter active zone length and a decrease of STP [<xref ref-type="bibr" rid="CR31">31</xref>]. Recently, the study of Telias et al. indicated fewer synaptic vesicles and spontaneous synaptic activity in FXS human embryonic stem cells [<xref ref-type="bibr" rid="CR39">39</xref>]. In our study, we showed that FMRP depletion causes a decrease of synaptic vesicle recycling in both strong and weak unloading boutons in the hippocampus, while the amount of synaptic boutons remained unchanged between <italic>Fmr1</italic> KO and WT mice.</p>
<p>Only male mice were investigated in this study. Therefore, the proteomic changes relevant to ASD highlight the changes seen in the male sex. Although only <italic>Fmr1</italic> KO mice were investigated, differences in mouse genetic background between the tissue and synaptosome samples (see “<xref ref-type="sec" rid="Sec2">Methods</xref>” section) might influence the results.</p>
</sec>
<sec id="Sec17">
<title>Conclusions</title>
<p>Taken together, our findings demonstrate that a lack of FMRP is associated with differences in synaptic vesicle dynamics in both hippocampal and cerebellar neurons (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). Synaptic vesicles are critical for synaptic transmission in the nervous system, and inefficient synaptic transmission in the hippocampus and cerebellum could impair memory formation and motor learning in fragile X and possibly autism spectrum disorder (ASD) patients.<fig id="Fig4"><label>Fig. 4</label><caption><p>Changes observed in hippocampal and cerebellar synapses using mass spectrometry and microscopy studies. In the hippocampus (<italic>above</italic>), significant changes were observed for ATPases and a significant decrease of GABA receptor proteins. Furthermore, the microscopy studies indicated decreased synaptic vesicle release in hippocampal neurons. This might indicate decreased excitatory synaptic transmission in the hippocampus. A significant increase of ATPases, GABA and glutamate receptors and synaptic vesicle proteins were observed in cerebellar synapses (<italic>below</italic>). This increase in synaptic activity was also supported by the microscopy studies, in which cerebellar neurons show an increase of synaptic vesicle dynamics, suggesting an increased inhibitory output from the cerebellum</p></caption><graphic id="MO4" xlink:href="13229_2016_80_Fig4_HTML"></graphic></fig></p>
</sec>
</body>
<back>
<app-group>
<app id="App1">
<sec id="Sec18">
<title>Additional file</title>
<p>
<media id="MOESM1" position="anchor" xlink:href="13229_2016_80_MOESM1_ESM.docx">
<label>Additional file 1:</label>
<caption>
<p>Supplementary methods information, figures of principal component analysis (PCA), GO term analysis heatmap, live-cell imaging setup and number of synaptic boutons, and tables with a full list of significant changed proteins in mouse brain tissue and synaptosome fractions in LC-MS<sup>E</sup> and GO term enrichment results. (DOCX 405 kb)</p>
</caption>
</media>
</p>
</sec>
</app>
</app-group>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AT1A1</term>
<def>
<p>sodium potassium transporting ATPase alpha 1</p>
</def>
</def-item>
<def-item>
<term>AT1A3</term>
<def>
<p>sodium potassium transporting ATPase alpha 3</p>
</def>
</def-item>
<def-item>
<term>AT1B1</term>
<def>
<p>sodium potassium transporting ATPase beta 1</p>
</def>
</def-item>
<def-item>
<term>AT1B2</term>
<def>
<p>sodium potassium transporting ATPase beta 2</p>
</def>
</def-item>
<def-item>
<term>AT2B2</term>
<def>
<p>plasma membrane calcium-transporting ATPase 2</p>
</def>
</def-item>
<def-item>
<term>AZ</term>
<def>
<p>active zone</p>
</def>
</def-item>
<def-item>
<term>BASP1</term>
<def>
<p>brain acid soluble protein 1</p>
</def>
</def-item>
<def-item>
<term>CB</term>
<def>
<p>cerebellum</p>
</def>
</def-item>
<def-item>
<term>CYFP</term>
<def>
<p>cytoplasmic FMRP-interacting protein</p>
</def>
</def-item>
<def-item>
<term>DCE1</term>
<def>
<p>glutamate decarboxylase 1</p>
</def>
</def-item>
<def-item>
<term>DCE2</term>
<def>
<p>glutamate decarboxylase 2</p>
</def>
</def-item>
<def-item>
<term>EAA1</term>
<def>
<p>excitatory amino acid transporter 1</p>
</def>
</def-item>
<def-item>
<term>FM1-43</term>
<def>
<p>n-(3-triethylammoniumpropyl)-4-(4-(dibutylamino) styryl) pyridinium dibromide</p>
</def>
</def-item>
<def-item>
<term>
<italic>Fmr1</italic>
</term>
<def>
<p>fragile X mental retardation 1 gene</p>
</def>
</def-item>
<def-item>
<term>FMRP</term>
<def>
<p>fragile X mental retardation protein</p>
</def>
</def-item>
<def-item>
<term>FXR2</term>
<def>
<p>fragile x mental retardation syndrome-related 2</p>
</def>
</def-item>
<def-item>
<term>FXS</term>
<def>
<p>fragile X syndrome</p>
</def>
</def-item>
<def-item>
<term>GABA</term>
<def>
<p>gamma-aminobutyric acid</p>
</def>
</def-item>
<def-item>
<term>GRIA</term>
<def>
<p>glutamate receptor</p>
</def>
</def-item>
<def-item>
<term>H1T</term>
<def>
<p>histone H1t</p>
</def>
</def-item>
<def-item>
<term>HC</term>
<def>
<p>hippocampus</p>
</def>
</def-item>
<def-item>
<term>KCD12</term>
<def>
<p>BTB POZ domain- containing protein KCTD12</p>
</def>
</def-item>
<def-item>
<term>KO</term>
<def>
<p>knockout</p>
</def>
</def-item>
<def-item>
<term>LC-MS<sup>E</sup></term>
<def>
<p>liquid-chromatography mass spectrometry</p>
</def>
</def-item>
<def-item>
<term>mGluR</term>
<def>
<p>metabotropic glutamate receptor</p>
</def>
</def-item>
<def-item>
<term>NEUM</term>
<def>
<p>neuromodulin</p>
</def>
</def-item>
<def-item>
<term>PC</term>
<def>
<p>peptide count</p>
</def>
</def-item>
<def-item>
<term>Q-TOF</term>
<def>
<p>quadrupole time-of-flight</p>
</def>
</def-item>
<def-item>
<term>RI</term>
<def>
<p>relative intensity</p>
</def>
</def-item>
<def-item>
<term>ROIs</term>
<def>
<p>regions of interest</p>
</def>
</def-item>
<def-item>
<term>SRM-MS</term>
<def>
<p>selected reaction monitoring mass spectrometry</p>
</def>
</def-item>
<def-item>
<term>SSDH</term>
<def>
<p>succinate semialdehyde dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>STP</term>
<def>
<p>short-term plasticity</p>
</def>
</def-item>
<def-item>
<term>SV2A</term>
<def>
<p>synaptic vesicle glycoprotein 2A</p>
</def>
</def-item>
<def-item>
<term>SV2B</term>
<def>
<p>synaptic vesicle glycoprotein 2B</p>
</def>
</def-item>
<def-item>
<term>VGLU1</term>
<def>
<p>vesicular glutamate transporter 1</p>
</def>
</def-item>
<def-item>
<term>WT</term>
<def>
<p>wild type</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Competing interests</bold>
</p>
<p>The authors declare no financial or non-financial competing interests. Yet, it should be noted that the ErasmusLadder has been designed by Neurasmus BV, which is a non-profit company of the Dept. of Neuroscience at Erasmus MC of which C.I.D.Z. is the chair. This equipment is now commercially available through Noldus BV. S.B. is the director of Psynova Neurotech Ltd.</p>
</fn>
<fn>
<p>
<bold>Authors’ contribution</bold>
</p>
<p>JB contributed to the study concept and design, acquisition of mass spectrometry and microscopy data, analysis and interpretation of all acquired data and writing the manuscript. This author declares no financial or non-financial competing interests. ZL contributed to the isolation of synaptosomes, guidance with cell culture and has been involved in revising the manuscript critically. This author declares no financial or non-financial competing interests. HMG contributed to the acquisition of live-cell imaging data, analysis and interpretation and has been involved in revising the manuscript critically providing important intellectual content. This author declares no financial or non-financial competing interests. HS helped with the analysis of LC-MS<sup>E</sup> data and has been involved in revising the manuscript critically. This author declares no financial or non-financial competing interests. EDH contributed to the acquisition of electron microscopy data and has been involved in revising the manuscript critically. This author declares no financial or non-financial competing interests. DC performed GO-enrichment analysis and has been involved in revising the manuscript critically. This author declares no financial or non-financial competing interests. SO, PhD, participated in SRM mass spectrometry and has been involved in revising the manuscript critically. This author declares no financial or non-financial competing interests. GWAC, PhD, provided the facilities and guidance for live-cell imaging and helped with the interpretation of the data and critical revision of the manuscript. This author declares no financial or non-financial competing interests. ABH, PhD, provided the facilities and guidance for live-cell imaging and helped with the interpretation of the data and critical revision of the manuscript. This author declares no financial or non-financial competing interests. RW, PhD, provided the mouse models and provided expert knowledge and helped with the writing of the manuscript. This author declares no financial or non-financial competing interests. CIZ, MD, PhD, contributed to the study supervision of the microscopy aspects, provided facilities for cell culture and electron microscopy and helped to write the manuscript. Furthermore, the ErasmusLadder has been designed by Neurasmus BV, which is a non-profit company of the Dept. of Neuroscience at Erasmus MC of which CIZ (similar as previous abbreviation) is the chair. SB, MD, PhD, contributed to the study concept, study design and supervision, provided facilities for mass spectrometry and co-wrote the manuscript. SB is the director of Psynova Neurotech Ltd. All authors read and approved the manuscript.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by the Dutch Organization for Medical Sciences (C.I.D.Z.), Life Sciences (C.I.D.Z.), Social and Behavioral Sciences (C.I.D.Z.), NeuroBasic (C.I.D.Z. and S.B.) and ERC-adv and ERC-POC of the EU (C.I.D.Z.).</p>
<sec id="FPar1">
<title>Study funding</title>
<p>This work was supported by Autism Speaks Grant #6009 and the Dutch Fund for Economic Structure Reinforcement (FES) under grant agreement number 0908 (NeuroBasic PharmaPhenomics Project).</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">de Vries BB, van den Ouweland AM, Mohkamsing S, Duivenvoorden HJ, Mol E, Gelsema K, et al. Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet. 1997;61:660–7.</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coffee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Keith</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Albizua</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mowrey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA</article-title>
<source/>Am J Hum Genet
          <year>2009</year>
<volume>85</volume>
<fpage>503</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2009.09.007</pub-id>
<pub-id pub-id-type="pmid">19804849</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijetunge</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Chattarji</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wyllie</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kind</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Fragile X syndrome: from targets to treatments</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>68</volume>
<fpage>83</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.11.028</pub-id>
<pub-id pub-id-type="pmid">23257237</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Recent advances in fragile X: a model for autism and neurodegeneration</article-title>
<source/>Curr Opin Psychiatry
          <year>2005</year>
<volume>18</volume>
<fpage>490</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1097/01.yco.0000179485.39520.b0</pub-id>
<pub-id pub-id-type="pmid">16639106</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klusek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Losh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Consistency between research and clinical diagnoses of autism among boys and girls with fragile X syndrome</article-title>
<source/>J Intellect Disabil Res
          <year>2014</year>
<volume>58</volume>
<fpage>940</fpage>
<lpage>952</lpage>
<pub-id pub-id-type="doi">10.1111/jir.12121</pub-id>
<pub-id pub-id-type="pmid">24528851</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antar</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Sunrise at the synapse: the FMRP mRNP shaping the synaptic interface</article-title>
<source/>Neuron
          <year>2003</year>
<volume>37</volume>
<fpage>555</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(03)00090-4</pub-id>
<pub-id pub-id-type="pmid">12597853</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>The mGluR theory of fragile X mental retardation</article-title>
<source/>Trends Neurosci
          <year>2004</year>
<volume>27</volume>
<fpage>370</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2004.04.009</pub-id>
<pub-id pub-id-type="pmid">15219735</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Annangudi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Luszpak</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hatcher</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Weiler</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Thornley</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Kile</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Wightman</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Greenough</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Sweedler</surname>
<given-names>JV</given-names>
</name>
</person-group>
<article-title>Neuropeptide release is impaired in a mouse model of fragile X mental retardation syndrome</article-title>
<source/>ACS Chem Neurosci
          <year>2010</year>
<volume>1</volume>
<fpage>306</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1021/cn900036x</pub-id>
<pub-id pub-id-type="pmid">20495672</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>P-Y</given-names>
</name>
<name>
<surname>Rotman</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Blundon JayÂ</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cavalli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zakharenko StanislavÂ</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Klyachko VitalyÂ</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels</article-title>
<source/>Neuron
          <year>2013</year>
<volume>77</volume>
<fpage>696</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.12.018</pub-id>
<pub-id pub-id-type="pmid">23439122</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Sojka</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Klyachko</surname>
<given-names>VA</given-names>
</name>
</person-group>
<article-title>Abnormal presynaptic short-term plasticity and information processing in a mouse model of fragile X syndrome</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>10971</fpage>
<lpage>10982</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2021-11.2011</pub-id>
<pub-id pub-id-type="pmid">21795546</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mientjes</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Nieuwenhuizen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hoogeveen-Westerveld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Severijnen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rife</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Oostra</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo</article-title>
<source/>Neurobiol Dis
          <year>2006</year>
<volume>21</volume>
<fpage>549</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2005.08.019</pub-id>
<pub-id pub-id-type="pmid">16257225</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinueza Veloz</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Buijsen</surname>
<given-names>RAM</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cupido</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bosman</surname>
<given-names>LWJ</given-names>
</name>
<name>
<surname>Koekkoek</surname>
<given-names>SKE</given-names>
</name>
<name>
<surname>Potters</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Oostra</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>De Zeeuw</surname>
<given-names>CI</given-names>
</name>
</person-group>
<article-title>The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice</article-title>
<source/>Genes Brain Behav
          <year>2012</year>
<volume>11</volume>
<issue>3</issue>
<fpage>325</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2011.00763.x</pub-id>
<pub-id pub-id-type="pmid">22257369</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrimpf</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Meskenaite</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rutishauser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aebersold</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sonderegger</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Proteomic analysis of synaptosomes using isotope-coded affinity tags and mass spectrometry</article-title>
<source/>Proteomics
          <year>2005</year>
<volume>5</volume>
<fpage>2531</fpage>
<lpage>2541</lpage>
<pub-id pub-id-type="doi">10.1002/pmic.200401198</pub-id>
<pub-id pub-id-type="pmid">15984043</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koekkoek</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Milojkovic</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Dortland</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Ruigrok</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Maex</surname>
<given-names>R</given-names>
</name>
<name>
<surname>De Graaf</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>VanderWerf</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome</article-title>
<source/>Neuron
          <year>2005</year>
<volume>47</volume>
<fpage>339</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2005.07.005</pub-id>
<pub-id pub-id-type="pmid">16055059</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broek</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Rahmoune</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bahn</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins</article-title>
<source/>Mol Autism
          <year>2014</year>
<volume>5</volume>
<fpage>41</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-41</pub-id>
<pub-id pub-id-type="pmid">25126406</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wesseling</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Want</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Rahmoune</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bahn</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Hippocampal proteomic and metabonomic abnormalities in neurotransmission, oxidative stress and apoptotic pathways in a chronic phencyclidine rat model</article-title>
<source/>J Proteome Res
          <year>2015</year>
<volume>14</volume>
<issue>8</issue>
<fpage>3174</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00105</pub-id>
<pub-id pub-id-type="pmid">26043028</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<mixed-citation publication-type="other">R Development Core Team (2011), R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing. ISBN: 3-900051-07-0. Available online at <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>.</mixed-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Picotti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Huttenhain</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heinzelmann-Schwarz</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jovanovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aebersold</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vitek</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Protein significance analysis in selected reaction monitoring (SRM) measurements</article-title>
<source/>Mol Cell Proteomics
          <year>2012</year>
<volume>11</volume>
<fpage>M111 014662</fpage>
<pub-id pub-id-type="doi">10.1074/mcp.M111.014662</pub-id>
<pub-id pub-id-type="pmid">22190732</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schindelin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arganda-Carreras</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Frise</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kaynig</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Longair</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pietzsch</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Preibisch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rueden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saalfeld</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fiji: an open-source platform for biological-image analysis</article-title>
<source/>Nat Methods
          <year>2012</year>
<volume>9</volume>
<fpage>676</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id>
<pub-id pub-id-type="pmid">22743772</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thevenaz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ruttimann</surname>
<given-names>UE</given-names>
</name>
<name>
<surname>Unser</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A pyramid approach to subpixel registration based on intensity</article-title>
<source/>IEEE Trans Image Process
          <year>1998</year>
<volume>7</volume>
<fpage>27</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1109/83.650848</pub-id>
<pub-id pub-id-type="pmid">18267377</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zelensky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Meijering</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van Cappellen</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>de Gruiter</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>van Belle</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>van Royen</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Houtsmuller</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Essers</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>BRCA2 diffuses as oligomeric clusters with RAD51 and changes mobility after DNA damage in live cells</article-title>
<source/>J Cell Biol
          <year>2014</year>
<volume>207</volume>
<fpage>599</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201405014</pub-id>
<pub-id pub-id-type="pmid">25488918</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meijering</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dzyubachyk</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Smal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Methods for cell and particle tracking</article-title>
<source/>Methods Enzymol
          <year>2012</year>
<volume>504</volume>
<fpage>183</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-391857-4.00009-4</pub-id>
<pub-id pub-id-type="pmid">22264535</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartolome-Martin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramirez-Franco</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sanchez-Prieto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Efficient synaptic vesicle recycling after intense exocytosis concomitant with the accumulation of non-releasable endosomes at early developmental stages</article-title>
<source/>J Cell Sci
          <year>2012</year>
<volume>125</volume>
<fpage>422</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.090878</pub-id>
<pub-id pub-id-type="pmid">22331355</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatemi</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Aldinger</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bauman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Blaha</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Blatt</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dager</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>PE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consensus paper: pathological role of the cerebellum in autism</article-title>
<source/>Cerebellum
          <year>2012</year>
<volume>11</volume>
<fpage>777</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.1007/s12311-012-0355-9</pub-id>
<pub-id pub-id-type="pmid">22370873</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Courchesne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Why the frontal cortex in autism might be talking only to itself: local over-connectivity but long-distance disconnection</article-title>
<source/>Curr Opin Neurobiol
          <year>2005</year>
<volume>15</volume>
<fpage>225</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2005.03.001</pub-id>
<pub-id pub-id-type="pmid">15831407</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myrick</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Poidevin</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Suhl</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Visootsak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cavalli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2015</year>
<volume>112</volume>
<fpage>949</fpage>
<lpage>956</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1423094112</pub-id>
<pub-id pub-id-type="pmid">25561520</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidorov</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Auerbach</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein and synaptic plasticity</article-title>
<source/>Mol Brain
          <year>2013</year>
<volume>6</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1186/1756-6606-6-15</pub-id>
<pub-id pub-id-type="pmid">23566911</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<mixed-citation publication-type="other">Rossier BC, Geering K, Kraehenbuhl JP: Regulation of the sodium pump: how and why? Trends in Biochemical Sciences, 12:483–487</mixed-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nathanson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Scavone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scanlon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McKee</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The cellular Na+ pump as a site of action for carbon monoxide and glutamate: a mechanism for long-term modulation of cellular activity</article-title>
<source/>Neuron
          <year>1995</year>
<volume>14</volume>
<fpage>781</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.1016/0896-6273(95)90222-8</pub-id>
<pub-id pub-id-type="pmid">7718240</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vanderklish</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>JR</given-names>
<suffix>3rd</suffix>
</name>
</person-group>
<article-title>Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2008</year>
<volume>105</volume>
<fpage>15281</fpage>
<lpage>15286</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0804678105</pub-id>
<pub-id pub-id-type="pmid">18829439</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klemmer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Meredith</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Klychnikov</surname>
<given-names>OI</given-names>
</name>
<name>
<surname>Stahl-Zeng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Schors</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Wortel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Spijker</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomics, ultrastructure, and physiology of hippocampal synapses in a fragile X syndrome mouse model reveal presynaptic phenotype</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>25495</fpage>
<lpage>25504</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.210260</pub-id>
<pub-id pub-id-type="pmid">21596744</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mercaldo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Boyl</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Eleuteri</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zalfa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Rubeis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Di Marino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Massimi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Falconi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP</article-title>
<source/>Cell
          <year>2008</year>
<volume>134</volume>
<fpage>1042</fpage>
<lpage>1054</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.07.031</pub-id>
<pub-id pub-id-type="pmid">18805096</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>O'Connor</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Siomi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dutra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nussbaum</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Dreyfuss</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2</article-title>
<source/>EMBO J
          <year>1995</year>
<volume>14</volume>
<fpage>5358</fpage>
<lpage>5366</lpage>
<pub-id pub-id-type="pmid">7489725</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenck</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bardoni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bagni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2001</year>
<volume>98</volume>
<fpage>8844</fpage>
<lpage>8849</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.151231598</pub-id>
<pub-id pub-id-type="pmid">11438699</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Zeeuw</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Hoebeek</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Bosman</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Schonewille</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Witter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Koekkoek</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>Spatiotemporal firing patterns in the cerebellum</article-title>
<source/>Nat Rev Neurosci
          <year>2011</year>
<volume>12</volume>
<fpage>327</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3011</pub-id>
<pub-id pub-id-type="pmid">21544091</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suvrathan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hoeffer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chattarji</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<fpage>11591</fpage>
<lpage>11596</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1002262107</pub-id>
<pub-id pub-id-type="pmid">20534533</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hays</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bureau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>A target cell-specific role for presynaptic Fmr1 in regulating glutamate release onto neocortical fast-spiking inhibitory neurons</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<fpage>2593</fpage>
<lpage>2604</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2447-12.2013</pub-id>
<pub-id pub-id-type="pmid">23392687</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nieto-Rostro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium channel density</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>3628</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms4628</pub-id>
<pub-id pub-id-type="pmid">24709664</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Telias</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuznitsov-Yanovsky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ben-Yosef</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Functional deficiencies in fragile X neurons derived from human embryonic stem cells</article-title>
<source/>J Neurosci
          <year>2015</year>
<volume>35</volume>
<fpage>15295</fpage>
<lpage>15306</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0317-15.2015</pub-id>
<pub-id pub-id-type="pmid">26586818</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>